ABSTRACT
Results:
The average monthly abandonment rate was 12.5% (2014) , 12.9% (2015) , and 14.3% (2016) . The cost savings from tests not performed for this 3-year period was $696,007. Molecular hematopathology assays were the most frequently ordered tests, with variable abandonment rates.
Conclusions: Although this CDST was passive (ie, could be overridden at the point of order entry) and was associated with a relatively low abandonment rate, it achieved a considerable cost savings each year since each abandoned test saved the institution $1,000 or more.
Increasing emphasis on value-based care encourages health care providers to develop evidence-based, best-practice approaches for patient care that maintain or improve the quality of care while decreasing waste and lowering costs. 1 This shift from volume to value has necessitated a reassessment of all components of medical service lines to ensure that each component provided is truly necessary and contributes to positive patient outcomes. The implementation of new legislation (eg, Medicare Access and Chip Reauthorization Act of 2015) and the bundling of payments for particular diagnoses and procedures similarly encourage review of each aspect of the health care delivery process to reduce unnecessary costs while preserving or improving quality. 2, 3 The importance of laboratory-based testing for the diagnosis and management of patients is well established. However, there is general agreement that laboratory testing is overused, provides little clinical utility when ordered without clear indication, and may, in some cases, be detrimental to patient care. 4, 5 The elimination of unnecessary testing is a means by which health care systems can reduce cost while improving patient care, patient satisfaction, and quality.
The widespread implementation of the electronic health record (EHR) with computerized physician/provider order entry has offered new means to detect and correct unnecessary orders before specimens are collected and submitted to the laboratory. 6 Data within the computer system can be used to determine the validity of a test request at the moment of order entry, and an intervention can be initiated. Clinical decision support tools (CDSTs) with limited functionality are currently available in EHR systems; more sophisticated interventions can be achieved with custom programming.
Our institution has employed a variety of techniques, including several CDSTs, to avert unnecessary testing and to guide providers to the appropriate tests for their patients. [7] [8] [9] We discovered, through a review of expensive test orders and associated medical records, that some of the expensive tests were likely unnecessary. We also found that some of our clinicians were unaware of test costs and the potential for financial burden on their patients for costs not covered by their insurance. Although the reports of impact are variable, some institutions have demonstrated a measurable decrease in order volumes when test costs are displayed. [10] [11] [12] At our institution, we implemented a CDST that notified the ordering provider when an expensive test was selected (ie, ≥$1,000) and requested that they consider carefully if the test was truly needed for patient care.
Materials and Methods
Initially, we reviewed the costs of all tests on our menu and collated a list of tests with a cost of $1,000 or more. These tests were categorized in $1,000 increments, beginning at $1,000 or more. This threshold was selected as it represented a number and volume of tests that we thought should show a reasonable savings, even with a relatively low abandonment rate. In addition, the number of tests for which the alert would be active was small enough, so that the interventions would not generate alert fatigue among providers and be ignored. Cost for tests performed in our laboratory was defined as the cost of materials and labor. The price paid by our organization for reference laboratory testing was the cost used for these tests. Test costs, not charges, were used for all cost reduction calculations.
The CDST used for this initiative was largely available within the functionality of the Epic system (Epic Systems, Verona, WI), which is the EHR used at our institution, but some customization was employed. This CDST presented a verify-at-order-entry question to which the provider was required to respond in order to proceed. This alert notified the provider that the test being ordered was expensive and demonstrated the test cost category in thousand-dollar increments (ie, ≥$1,000, ≥$2,000, etc). It also informed them that charges for testing may be substantially greater than costs and that patients may be responsible for charges not covered by insurance. The provider then had to decide whether or not to proceed with the order.
We reviewed data continuously gathered and collated monthly for 3 years for the Expensive Test Notification CDST described above. The intervention reports listed the type of test for which the alert was activated, the identity of the provider, and whether or not the provider proceeded with or abandoned the order. The abandonment rate was determined each month for all tests for which this CDST was active. When the provider decided that the test was not needed, a cost savings was determined based on the test costs, as described above. Other laboratory stewardship interventions that were undertaken that may have also influenced the clinical decision making regarding the tests in this cohort were noted. We assessed percent differences in the abandonment rate by cost category by χ 2 analysis using EpiCalc 2000 (Brixton Health, http:// www.brixtonhealth.com/).
Results
Thirty-six tests met the criteria for inclusion on the initial Expensive Test Notification list in 2014. This increased to 43 tests in 2015 and 67 tests in 2016, as new tests were added to our menu. The number of tests in the various cost ranges of the final list was as follows: $1,000 to $1,999 (49 tests), $2,000 to $2,999 (nine tests), $3,000 to $3,999 (three tests), $4,000 to $4,999 (zero tests), $5,000 to $5,999 (two tests), $6,000 to $6,999 (one test), $7,000 to $7,999 (zero tests), $8,000 to $8,999 (one test), and $9,000 to $9,999 (two tests).
The number of alert activations, the abandonment rate, and the cost savings are shown ❚Table 1❚. In brief, the Expensive Test Notification CDST was activated 3,448 times in 3 years, which resulted in the abandonment of 456 tests orders (ie, an overall abandonment rate of 13.2%). The cost savings associated with this intervention over 3 years was $696,007.
The monthly abandonment rate ranged from 5.5% to 17.2% in 2014, with an average of 12.5%. It ranged from 7.4% to 20.3% in 2015, with an average of 12.9%, and in 2016 ranged from 10.7% to 20.5%, with an average of 14.3%. The volume and abandonment rates for the top five tests for which the Expensive Test Notification CDST was activated each year are shown ❚Figure 1❚.
Most of the expensive tests were in the $1,000 or more category, with too few tests in the remaining categories for valid categorical comparisons. Therefore, the abandonment rate for the tests in the $1,000 or more category was compared with an aggregate of the abandonment frequencies from all the remaining, more expensive categories (ie, >$2,000, >$3,000, etc). The abandonment frequencies between the $1,000 or more category (12.2%) and the composite from the more expensive categories (16.4%), however, were not statistically significantly different (χ 2 P = .11). Hematology-oncology tests accounted for the highest volume of expensive testing in each of the 3 years. In 2014, the highest volume test was an oncologic oligonucleotide + single-nucleotide polymorphism (SNP)
The myeloma gene expression microarray, as well as fluorescent in situ hybridization panels for myelodysplasia and plasma cell myeloma, remained among the top five tests by volume over the 3 years. The test volumes for these tests increased over this period, while abandonment rates for these tests decreased or remained low.
The other tests that appeared among the top five expensive tests in at least one of the 3 years studied included NOD2/CARD15 gene sequencing (66 orders in 2014), a multigene hereditary pancreatitis panel (41 orders in 2016), a neurological paraneoplastic panel (66 orders in 2015), and a universal microbial identification panel (125 orders in 2016). Among these tests, abandonment ranged from 6.1% for NOD2/CARD15 sequencing to 43.9% for the paraneoplastic panel. There was a 35.0% abandonment rate for universal microbial identification, which was thought to also be influenced by real-time case-based interventions, presentations (data not shown), and a publication that demonstrated the limited usefulness of this technology for mycobacteria and fungi in the absence of histopathologic or microbiologic evidence (eg, positive smear) of disease. 13 Over the 3-year period, there were 545 unique ordering providers. During each year, approximately 90.8% (range, 88.2%-92.5%) of providers entered 10 or fewer expensive orders, which accounted for an average of 40.2% of total orders for each year (range, 28.8%-50.5%). Overall, these providers abandoned 25.6% of orders. Only 9.2% of the providers entered more than 10 expensive orders per year (range, 7.5%-11.8%), which accounted for 59.8% (49.6%-71.2%) of all orders entered. The providers that used these tests more frequently abandoned only 5.0% of their orders following the activation of the Expensive Test Notification CDST.
Molecular-based testing for germline genetic conditions constituted 22.2% of all expensive test orders (766/3,448) and had an average abandonment rate of 12.9%. Molecular-based testing for oncologic conditions accounted for 67.5% of all orders, with an average abandonment rate of 8.7%. Testing in the infectious disease category accounted for 4.9% of all orders, whereas expensive neurologic tests accounted for 5.3% of all orders.
Discussion
The goal of this project was to review the effectiveness of a passive electronic notification that an expensive test was being ordered. The term passive in this context denotes a CDST that the provider can override at the point of order entry (ie, a soft stop); this is in contrast to a hard stop intervention wherein an electronic override is not possible and an override must be achieved by another mechanism (eg, calling the laboratory or seeking approval from an oversight body to proceed with testing). The evidence-based accuracy of the individual's decision to order or not order the test was not the focus of this project and was not reviewed. However, a review of such data, which is largely available in the medical record, could be used by practice groups (eg, service lines) to examine the variability between practitioners and work toward standardization, as appropriate.
Passive alerts, such as the one studied here, are less disruptive to the care delivery process (ie, the provider does not have to stop and seek permission to complete the test order) but are also less effective in stopping unnecessary testing. 7 The choice of which type of alert to use should be thoughtfully made based on the medical importance of the intervention, the impact on medical operation (ie, care delivery and financial impact), and provider satisfaction. Our intervention targeted expensive tests, the overuse of which is important in addressing care affordability. We chose a passive alert for this intervention, based on our knowledge of ordering frequency of these tests, to balance the reduction of unnecessary costly testing with provider satisfaction and minimal to no disruption to clinical workflow. Based on previous studies, we had no patient safety concerns with this intervention, since all providers have the authority to override the intervention to complete the test order.
The display of cost with the associated test has had a variable impact on the reduction of testing for laboratory and radiologic studies. Some studies have demonstrated a reduction in testing associated with the display of costs, whereas a number of studies have not. 10, [14] [15] [16] [17] Given the lack DOI: 10.1093/ajcp/aqy021 © American Society for Clinical Pathology of clarity with respect to an outcome, we chose to target only high-cost tests (ie, ≥$1,000), with the expectation that even a relatively low abandonment rate would result in a reasonable cost savings, which in fact was the case. Although the Expensive Test Notification CDST deterred the ordering of only 13.3% of the tests for which it was activated over 3 years, the resulting cost savings of $696,007 was substantial. Although the tests in the categories of $2,000 and above were abandoned at a slightly higher rate (16.4%) compared with those in the $1,000 or more category (12.2%), the difference was not statistically significant (P = .11).
There are approximately 3,400 physicians employed in our health care organization, as well as nearly 1,900 physician trainees and a large number of providers with varying degrees of ordering privileges. Over the course of 3 years, only 545 unique providers were responsible for ordering tests that cost $1,000 or more. In a menu of more than 2,500 test options, only 67 tests met the criteria for expensive test notification. Therefore, a small set of expensive tests is ordered by a relatively small group of providers, which is an important parameter when considering interventions strategies. There have been no complaints concerning this intervention with respect to patient safety, disruption of care delivery, or provider satisfaction.
The review of the data from this intervention provides a number of interesting and useful insights for future interventions. These concern the types of expensive tests ordered, the types of providers more likely to abandon a test when receiving this type of alert, and, finally, the added benefit when proactive intervention is combined with passive clinical decision support. In addition to cost savings, one could also consider studying ordering patterns of individual providers as a means of studying intervention effectiveness.
Molecular oncologic tests for hematopoietic disorders were consistently among the highest volume expensive tests ordered. These had variable abandonment rates ranging from 0% to 25.0%. A review of the tests that were abandoned revealed some opportunities for improvement in developing and/or standardizing test algorithms. The time period studied coincided with a shift in practice, with a decrease in chromosomal microarrays along with an increase in gene sequencing and gene expression prognostic testing. An evidence-based, consensus approach for the use of these tests may have decreased the variability of the ordering patterns. In such a scenario, the abandonment rate would be expected to be very low since it would be agreed upon which tests were needed, as defined by the diagnostic algorithm.
Some tests, particularly those for inherited genetic disorders, had a high frequency of abandonment. In 2014, for example, gene sequencing of PSEN1 (early-onset Alzheimer disease), CDKL5 (atypical Rett syndrome), and SCN1A (epilepsy) was ordered very infrequently, and orders for these tests were uniformly abandoned. This pattern suggests that these tests may have been misordered or were orders of curiosity, and when confronted with the high cost of the assay, the provider determined the test was not necessary for medical care. Importantly, all of these orders would have been completed if the expensive test intervention had not been in place.
Interestingly, the more frequent users of expensive tests were less likely to abandon the test when confronted by the cost of the test. This suggests that these providers were more knowledgeable about the test and the clinical setting in which the test is needed, regardless of the cost. The less frequent, and possibly less experienced, users had a higher abandonment rate, which suggests the Expensive Test Notification CDST gave them pause wherein they had to reconsider if the test was truly necessary for patient care. Some of the abandonments from these providers could also have been due to misorders or curiosity orders.
There were two instances wherein individuals undertook active initiatives that influenced the ordering of tests on the expensive test notification list. Evident overuse of the oncologic oligonucleotide + SNP chromosomal microarray was noted by the cytogeneticist, who in 2015 made efforts to interact with providers to determine if the excessive testing was necessary. Similarly, studies in clinical microbiology showed that molecular testing for mycobacteria and fungi from clinical specimens without evidence of disease caused by these organisms was wasteful and noncontributory to patient care. These data were shared with the infectious diseases department, and efforts were made to curtail unnecessary testing. Both of these examples, although not coordinated with this intervention, strongly suggest that active interventions in conjunction with passive interventions are more effective than passive interventions alone.
In conclusion, notification of providers that an expensive test is being ordered can result in substantial cost savings. The abandonment rate varies among individuals, and data gathered in this regard can be used to tailor education and future interventions. Similarly, the data gathered demonstrate the categories and frequency of expensive tests being ordered, which can be used to focus efforts on the development of best-practice algorithms and other interventions that affect patient care and improve the value of health care services. 
